An emerging adeno-associated viral vector pipeline for cardiac gene therapy

Human Gene Therapy

Volumn 24, Issue 11, 2013, Pages 906-913

  Asokan, Aravind ^a   Samulski, R Jude ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARVOVIRUS VECTOR;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS 1; ADENO ASSOCIATED VIRUS 2; ADENO ASSOCIATED VIRUS 3; ADENO ASSOCIATED VIRUS 6; ADENO ASSOCIATED VIRUS 7; ADENO ASSOCIATED VIRUS 8; ADENO ASSOCIATED VIRUS 9; CARDIOVASCULAR DISEASE; COMBINATORIAL LIBRARY; CONGESTIVE CARDIOMYOPATHY; HEART FAILURE; HUMAN; IMMUNITY; NONHUMAN; REVIEW; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; VIROGENESIS; VIRUS CAPSID; VIRUS ISOLATION; VIRUS RECOMBINANT; VIRUS STRAIN;

ANIMALS; CARDIOVASCULAR DISEASES; DEPENDOVIRUS; GENETIC THERAPY; GENETIC VECTORS; HUMANS; SPECIES SPECIFICITY;

EID: 84886771583     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2013.2515     Document Type: Review

References (99)

1. Agbandje-Mckenna, M., and Kleinschmidt, J. (2011). AAV capsid structure and cell interactions. Methods Mol. Biol. 807, 47-92.
2. Agrawal, R.S., Muangman, S., Layne, M.D., et al. (2004). Preemptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival. Gene Ther. 11, 962-969. (Pubitemid 38923620)
3. Aikawa, R., Huggins, G.S., and Snyder, R.O. (2002). Cardio-myocyte- specific gene expression following recombinant adeno-associated viral vector transduction. J. Biol. Chem. 277, 18979-18985. (Pubitemid 34952460)
4. Altheide, T.K., Hayakawa, T., Mikkelsen, T.S., et al. (2006). System-wide genomic and biochemical comparisons of sialic acid biology among primates and rodents: evidence for two modes of rapid evolution. J. Biol. Chem. 281, 25689-25702. (Pubitemid 44401958)
5. Andino, L.M., Takeda, M., Kasahara, H., et al. (2008). AAV-mediated knockdown of phospholamban leads to improved contractility and calcium handling in cardiomyocytes. J. Gene Med. 10, 132-142. (Pubitemid 351267155)
6. Asokan, A., Conway, J.C., Phillips, J.L., et al. (2010). Re-engineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28, 79-82.
7. Bell, C.L., Vandenberghe, L.H., Bell, P., et al. (2011). The AAV9 receptor and its modification to improve in vivo lung gene transfer in mice. J. Clin. Invest. 121, 2427-2435.
8. Bish, L.T., Morine, K., Sleeper, M.M., et al. (2008a). Adeno-as-sociated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359-1368.
9. Bish, L.T., Morine, K., Sleeper, M.M., et al. (2008b). Adeno-as-sociated virus (AAV) serotype 9 provides global cardiac gene transfer superior to AAV1, AAV6, AAV7, and AAV8 in the mouse and rat. Hum. Gene Ther. 19, 1359-1368.
10. Bish, L.T., Sleeper, M.M., Brainard, B., et al. (2008c). Percutaneous transendocardial delivery of self-complementary ade-no-associated virus 6 achieves global cardiac gene transfer in canines. Mol. Ther. 16, 1953-1959.
11. Bish, L.T., Sleeper, M.M., Forbes, S.C., et al. (2012). Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping. Mol. Ther. 20, 580-589.
12. Bostick, B., Yue, Y., Lai, Y., et al. (2008). Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates elec-trocardiographic abnormalities in mdx mice. Hum. Gene Ther. 19, 851-856.
13. Bowles, D.E., Rabinowitz, J.E., and Samulski, R.J. (2006). The genus Dependovirus. In Parvoviruses. J.R. Kerr, S.F. Cotmore, M.E. Bloom, et al., eds. (Edward Arnold Ltd., New York, NY), pp. 15-24.
14. Bowles, D.E., McPhee, S.W., Li, C., et al. (2012). Phase 1 gene therapy for Duchenne muscular dystrophy using a transla-tional optimized AAV vector. Mol. Ther. 20, 443-455.
15. Byrne, M.J., Power, J.M., Preovolos, A., et al. (2008). Recirculating cardiac delivery of AAV2/1SERCA2a improves myocardial function in an experimental model of heart failure in large animals. Gene Ther. 15, 1550-1557.
16. Champion, H.C., Georgakopoulos, D., Haldar, S., et al. (2003). Robust adenoviral and adeno-associated viral gene transfer to the in vivo murine heart: application to study of phospho-lamban physiology. Circulation 108, 2790-2797. (Pubitemid 37498982)
17. Cohen, M., and Varki, A. (2010). The sialome-far more than the sum of its parts. Omics 14, 455-464.
18. Denard, J., Beley, C., Kotin, R., et al. (2012). Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. J. Virol. 86, 6620-6631.
19. Denard, J., Marolleau, B., Jenny, C., et al. (2013). C-reactive protein (CRP) is essential for efficient systemic transduction of recombinant adeno-associated virus vector 1 (rAAV-1) and rAAV-6 in mice. J. Virol. 87, 10784-10791.
20. Du, L., Kido, M., Lee, D.V., et al. (2004). Differential myocardial gene delivery by recombinant serotype-specific adeno-associ-ated viral vectors. Mol. Ther. 10, 604-608. (Pubitemid 39186121)
21. Fang, H., Lai, N.C., Gao, M.H., et al. (2012). Comparison of adeno-associated virus serotypes and delivery methods for cardiac gene transfer. Hum. Gene Ther. Methods 23, 234-241.
22. Fargnoli, A.S., Katz, M.G., Yarnall, C., et al. (2013). Cardiac surgical delivery of the sarcoplasmic reticulum calcium ATPase rescues myocytes in ischemic heart failure. Ann. Thorac. Surg. 96, 586-595.
23. Ferrarini, M., Arsic, N., Recchia, F.A., et al. (2006). Adeno-associated virus-mediated transduction of VEGF165 improves cardiac tissue viability and functional recovery after permanent coronary occlusion in conscious dogs. Circ. Res. 98, 954-961.
24. Fish, K.M., Ladage, D., Kawase, Y., et al. (2013). AAV9.I-1c delivered via direct coronary infusion in a porcine model of heart failure improves contractility and mitigates adverse remodeling. Circ. Heart Fail. 6, 310-317.
25. Fraites, T.J., Jr., Schleissing, M.R., Shanely, R.A., et al. (2002). Correction of the enzymatic and functional deficits in a model of Pompe disease using adeno-associated virus vectors. Mol. Ther. 5, 571-578. (Pubitemid 34546087)
26. Gao, G., Bish, L.T., Sleeper, M.M., et al. (2011a). Transendocardial delivery of AAV6 results in highly efficient and global cardiac gene transferinRhesus macaques. Hum. Gene Ther. 22, 979-984.
27. Gao, G., Bish, L.T., Sleeper, M.M., et al. (2011b). Transendo-cardial delivery of AAV6 results in highly efficient and global cardiac gene transfer in rhesus macaques. Hum. Gene Ther. 22, 979-984.
28. Gregorevic, P., Blankinship, M.J., Allen, J.M., et al. (2004). Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nat. Med. 10, 828-834. (Pubitemid 39070856)
29. Gurda, B.L., Raupp, C., Popa-Wagner, R., et al. (2012). Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8. J. Virol. 86, 7739-7751.
30. Gurda, B.L., Dimattia, M.A., Miller, E.B., et al. (2013). Capsid antibodies to different adeno-associated virus serotypes bind common regions. J. Virol. 87, 9111-9124.
31. Hajjar, R.J. (2013). Potential of gene therapy as a treatment for heart failure. J. Clin. Invest. 123, 53-61.
32. Hajjar, R.J., Zsebo, K., Deckelbaum, L., et al. (2008). Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. J. Card. Fail. 14, 355-367. (Pubitemid 351756538)
33. Harbison, C.E., Weichert, W.S., Gurda, B.L., et al. (2012). Examining the cross-reactivity and neutralization mechanisms of a panel of mAbs against adeno-associated virus serotypes 1 and 5. J. Gen. Virol. 93, 347-355.
34. Hoshijima, M., Ikeda, Y., Iwanaga, Y., et al. (2002). Chronic suppression of heart-failure progression by a pseudopho-sphorylated mutant of phospholamban via in vivo cardiac rAAV gene delivery. Nat. Med. 8, 864-871.
35. Inagaki, K., Fuess, S., Storm, T.A., et al. (2006). Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol. Ther. 14, 45-53. (Pubitemid 43899488)
36. Iwanaga, Y., Hoshijima, M., Gu, Y., et al. (2004). Chronic phos-pholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats. J. Clin. Invest. 113, 727-736. (Pubitemid 38544166)
37. Kaplitt, M.G., Xiao, X., Samulski, R.J., et al. (1996). Long-term gene transfer in porcine myocardium after coronary infusion of an adeno-associated virus vector. Ann. Thorac. Surg. 62, 1669-1676. (Pubitemid 26421099)
38. Karakikes, I., Hadri, L., Rapti, K., et al. (2012). Concomitant intravenous nitroglycerin with intracoronary delivery of AAV1.SERCA2a enhances gene transfer in porcine hearts. Mol. Ther. 20, 565-571.
39. Kaspar, B.K., Roth, D.M., Lai, N.C., et al. (2005). Myocardial gene transfer and long-term expression following intracoronary delivery of adeno-associated virus. J. Gene Med. 7, 316-324. (Pubitemid 40443760)
40. Kawada, T., Nakazawa, M., Nakauchi, S., et al. (2002). Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc. Natl. Acad. Sci. USA 99, 901-906. (Pubitemid 34106608)
41. Kawamoto, S., Shi, Q., Nitta, Y., et al. (2005). Widespread and early myocardial gene expression by adeno-associated virus vector type 6 with a beta-actin hybrid promoter. Mol. Ther. 11, 980-985. (Pubitemid 40724117)
42. Kawase, Y., Ly, H.Q., Prunier, F., et al. (2008). Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure. J. Am. Coll. Cardiol. 51, 1112-1119. (Pubitemid 351374774)
43. Kern, A., Schmidt, K., Leder, C., et al. (2003). Identification of a heparin-binding motif on adeno-associated virus type 2 cap-sids. J. Virol. 77, 11072-11081. (Pubitemid 37204297)
44. Kotchey, N.M., Adachi, K., Zahid, M., et al. (2011). A potential role of distinctively delayed blood clearance of recombinant adeno-associated virus serotype 9 in robust cardiac trans-duction. Mol. Ther. 19, 1079-1089.
45. Lai, Y., and Duan, D. (2012). Progress in gene therapy of dys-trophic heart disease. Gene Ther. 19, 678-685.
46. Lerch, T.F., O'Donnell, J.K., Meyer, N.L., et al. (2012). Structure of AAV-DJ, a retargeted gene therapy vector: cryo-electron microscopy at 4.5 A resolution. Structure 20, 1310-1320.
47. Li, J., Wang, D., Qian, S., et al. (2003). Efficient and long-term in-tracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther. 10, 1807-1813. (Pubitemid 37185138)
48. Li, C., Diprimio, N., Bowles, D.E., et al. (2012). Single amino acid modification of adeno-associated virus capsid changes trans-duction and humoral immune profiles. J. Virol. 86, 7752-7759.
49. Louis Jeune, V., Joergensen, J.A., Hajjar, R.J., and Weber, T. (2013). Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy. Hum. Gene Ther. Methods. 24, 59-67.
50. Maersch, S., Huber, A., Buning, H., et al. (2010). Optimization of stealth adeno-associated virus vectors by randomization of immunogenic epitopes. Virology 397, 167-175.
51. Maheshri, N., Koerber, J.T., Kaspar, B.K., and Schaffer, D.V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204. (Pubitemid 43221704)
52. McTiernan, C.F., Mathier, M.A., Zhu, X., et al. (2007). Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts. Gene Ther. 14, 1613-1622. (Pubitemid 350143187)
53. Melo, L.G., Agrawal, R., Zhang, L., et al. (2002). Gene therapy strategy for long-term myocardial protection using adeno-as-sociated virus-mediated delivery of heme oxygenase gene. Circulation 105, 602-607. (Pubitemid 34123435)
54. Mingozzi, F., and High, K.A. (2011). Therapeutic in vivo gene transfer for genetic disease using AAV: progress and challenges. Nat. Rev. Genet. 12, 341-355.
55. Muller, O.J., Leuchs, B., Pleger, S.T., et al. (2006). Improved cardiac gene transfer by transcriptional and transductional targeting of adeno-associated viral vectors. Cardiovasc. Res. 70, 70-78.
56. Ng, R., Govindasamy, L., Gurda, B.L., et al. (2010). Structural characterization of the dual glycan binding adeno-associated virus serotype 6. J. Virol. 84, 12945-12957.
57. Odom, G.L., Gregorevic, P., Allen, J.M., et al. (2008). Micro-utrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Mol. Ther. 16, 1539-1545.
58. Pacak, C.A., and Byrne, B.J. (2011). AAV vectors for cardiac gene transfer: experimental tools and clinical opportunities. Mol. Ther. 19, 1582-1590.
59. Pacak, C.A., Mah, C.S., Thattaliyath, B.D., et al. (2006). Re-combinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3-e9. (Pubitemid 44255502)
60. Palomeque, J., Chemaly, E.R., Colosi, P., et al. (2007). Efficiency of eight different AAV serotypes in transducing rat myocardium in vivo. Gene Ther. 14, 989-997.
61. Petrs-Silva, H., Dinculescu, A., Li, Q., et al. (2011a). Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 19, 293-301.
62. Petrs-Silva, H., Dinculescu, A., Li, Q., et al. (2011b). Novel properties of tyrosine-mutant AAV2 vectors in the mouse retina. Mol. Ther. 19, 293-301.
63. Piacentino, V., 3rd, Milano, C.A., Bolanos, M., et al. (2012). X-linked inhibitor of apoptosis protein-mediated attenuation of apoptosis, using a novel cardiac-enhanced adeno-associated viral vector. Hum. Gene Ther. 23, 635-646.
64. Pleger, S.T., Most, P., Boucher, M., et al. (2007). Stable myocar-dial-specific AAV6-S100A1 gene therapy results in chronic functional heart failure rescue. Circulation 115, 2506-2515. (Pubitemid 46763224)
65. Pleger, S.T., Shan, C., Ksienzyk, J., et al. (2011). Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model. Sci. Transl. Med. 3, 92ra64.
66. Prasad, K.M., Smith, R.S., Xu, Y., and French, B.A. (2011a). A single direct injection into the left ventricular wall of an adeno-associated virus 9 (AAV9) vector expressing extracellular super-oxide dismutase from the cardiac troponin-T promoter protects mice against myocardial infarction. J. Gene Med. 13, 333-341.
67. Prasad, K.M., Xu, Y., Yang, Z., et al. (2011b). Robust cardio-myocyte-specific gene expression following systemic injection of AAV: in vivo gene delivery follows a Poisson distribution. Gene Ther. 18, 43-52.
68. Pulicherla, N., Shen, S., Yadav, S., et al. (2011). Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol. Ther. 19, 1070-1078.
69. Qi, Y., Liu, X., Li, H., et al. (2010). Selective tropism of the re-combinant adeno-associated virus 9 serotype for rat cardiac tissue. J. Gene Med. 12, 22-34.
70. Qiao, C., Yuan, Z., Li, J., et al. (2012). Single tyrosine mutation in AAV8 and AAV9 capsids is insufficient to enhance gene delivery to skeletal muscle and heart. Hum. Gene Ther. Methods 23, 29-37.
71. Raake, P.W., Hinkel, R., Muller, S., et al. (2008). Cardio-specific long-term gene expression in a porcine model after selective pressure-regulated retroinfusion of adeno-associated viral (AAV) vectors. Gene Ther. 15, 12-17. (Pubitemid 350284205)
72. Raake, P.W., Schlegel, P., Ksienzyk, J., et al. (2013). AAV6.be-taARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model. Eur. Heart J. 34, 1437-1447.
73. Rapti, K., Louis-Jeune, V., Kohlbrenner, E., et al. (2012). Neutralizing antibodies against AAV serotypes 1, 2, 6, and 9 in sera of commonly used animal models. Mol. Ther. 20, 73-83.
74. Scimia, M.C., Cannavo, A., and Koch, W.J. (2013). Gene therapy for heart disease: molecular targets, vectors and modes of delivery to myocardium. Expert Rev. Cardiovasc. Ther. 11, 999-1013.
75. Shen, S., Byrant, K.D., Brown, S.M., et al. (2011). Terminal N-linked galactose is the primary receptor for adeno-associ-ated virus 9. J. Biol. Chem. 286, 13532-13540.
76. Shen, S., Bryant, K., Sun, J., et al. (2012). Glycan binding avidity determines the systemic fate of adeno-associated virus 9. J. Virol. 86, 10408-10417.
77. Shen, S., Horowitz, E.D., Troupes, A.N., et al. (2013). Engraft-ment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. J. Biol. Chem. 288, 28814-28823.
78. Su, H., Lu, R., and Kan, Y.W. (2000). Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart. Proc. Natl. Acad. Sci. USA 97, 13801-13806.
79. Su, H., Arakawa-Hoyt, J., and Kan, Y.W. (2002). Adeno-associated viral vector-mediated hypoxia response element-regulated gene expression in mouse ischemic heart model. Proc. Natl. Acad. Sci. USA 99, 9480-9485. (Pubitemid 34764639)
80. Su, H., Joho, S., Huang, Y., et al. (2004). Adeno-associated viral vector delivers cardiac-specific and hypoxia-inducible VEGF expression in ischemic mouse hearts. Proc. Natl. Acad. Sci. USA 101, 16280-16285. (Pubitemid 39552836)
81. Su, H., Huang, Y., Takagawa, J., et al. (2006). AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Gene Ther. 13, 1495-1502. (Pubitemid 44567147)
82. Su, H., Yeghiazarians, Y., Lee, A., et al. (2008). AAV serotype 1 mediates more efficient gene transfer to pig myocardium than AAV serotype 2 and plasmid. J. Gene Med. 10, 33-41.
83. Svensson, E.C., Marshall, D.J., Woodard, K., et al. (1999). Efficient and stable transduction of cardiomyocytes after intramyocardial injection or intracoronary perfusion with recombinant adeno-associated virus vectors. Circulation 99, 201-205. (Pubitemid 29056359)
84. Tang, T., Gao, M.H., and Hammond, H.K. (2012). Prospects for gene transfer for clinical heart failure. Gene Ther. 19, 606-612.
85. Townsend, D., Blankinship, M.J., Allen, J.M., et al. (2007). Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Mol. Ther. 15, 1086-1092. (Pubitemid 46813611)
86. Varki, A., and Schauer, R. (2009). Sialic acids. In Essentials of Glycobiology. A. Varki, R.D. Cummings, J.D. Esko, et al., eds. (The Consortium of Glycobiology Editors, La Jolla, CA). pp. 199-218.
87. Wang, Z., Zhu, T., Qiao, C., et al. (2005). Adeno-associated virus serotype 8 efficiently delivers genes to muscle and heart. Nat. Biotechnol. 23, 321-328. (Pubitemid 41094420)
88. Weller, M.L., Amornphimoltham, P., Schmidt, M., et al. (2010). Epidermal growth factor receptor is a co-receptor for adeno-associated virus serotype 6. Nat. Med. 16, 662-664.
89. White, J.D., Thesier, D.M., Swain, J.B., et al. (2011). Myocardial gene delivery using molecular cardiac surgery with recombi-nant adeno-associated virus vectors in vivo. Gene Ther. 18, 546-552.
90. Wu, Z., Asokan, A., Grieger, J.C., et al. (2006a). Single amino acid changes can influence titer, heparin binding, and tissue tro-pism in different adeno-associated virus serotypes. J. Virol. 80, 11393-11397. (Pubitemid 44706580)
91. Wu, Z., Miller, E., Agbandje-Mckenna, M., and Samulski, R.J. (2006b). Alpha2, 3 and alpha2, 6 N-linked sialic acids facilitate efficient binding and transduction by adeno-associated virus types 1 and 6. J. Virol. 80, 9093-9103. (Pubitemid 44359983)
92. Xie, Q., Lerch, T.F., Meyer, N.L., and Chapman, M.S. (2011). Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6). Virology 420, 10-19.
93. Yang, L., Jiang, J., Drouin, L.M., et al. (2009). A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl. Acad. Sci. USA 106, 3946-3951.
94. Yasukawa, H., Yajima, T., Duplain, H., et al. (2003). The suppressor of cytokine signaling-1 (SOCS1) is a novel therapeutic target for enterovirus-induced cardiac injury. J. Clin. Invest. 111, 469-478. (Pubitemid 36228004)
95. Ying, Y., Muller, O.J., Goehringer, C., et al. (2010). Heart-targeted adeno-associated viral vectors selected by in vivo biopanning of a random viral display peptide library. Gene Ther. 17, 980-990.
96. Yue, Y., Li, Z., Harper, S.Q., et al. (2003). Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation 108, 1626-1632. (Pubitemid 37187791)
97. Zhong, L., Li, B., Mah, C.S., et al. (2008). Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc. Natl. Acad. Sci. USA 105, 7827-7832. (Pubitemid 351872723)
98. Zhu, T., Zhou, L., Mori, S., et al. (2005). Sustained whole-body functional rescue in congestive heart failure and muscular dystrophy hamsters by systemic gene transfer. Circulation 112, 2650-2659. (Pubitemid 41532602)
99. Zincarelli, C., Soltys, S., Rengo, G., et al. (2010). Comparative cardiac gene delivery of adeno-associated virus serotypes 1-9 reveals that AAV6 mediates the most efficient transduction in mouse heart. Clin. Transl. Sci. 3, 81-89.